CORAL GABLES, Fla. – Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, and KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically...
treatment News
CORAL GABLES, Fla. — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted...
Houston, Texas – Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. Published today in Nature...
Among patients with CD70-positive acute myeloid leukemia (AML), CD-70 targeting chimeric antigen receptor (CAR) T-cell therapy may be a promising therapeutic strategy, according to a cell line-based study published in Blood. AML is the most commonly diagnosed leukemia subtype among adults. Although treatment options have improved over the past several decades,...
MINNEAPOLIS, Minn. — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in its Phase 1b/2 study (CELC-G-201) evaluating gedatolisib in combination with Nubeqa® (darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with metastatic...
MIAMI, FLORIDA – A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. While the study doesn’t answer the...
Sugar Land, TX – Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles. Traditional therapies have improved survival rates, but new strategies are essential for more durable responses. Among the emerging therapeutic options, Natural Killer...
Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity Novel Globin-Switching mechanism derived from Cellarity’s AI-powered transcriptomic discovery platform SOMERVILLE, Mass. — Cellarity, a biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced that the first...
CAMBRIDGE, England & BOSTON, Mass.— CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating inobrodib 20 mg in combination with standard doses of pomalidomide (pom) and dexamethasone...
HAMPTON, N.J., – Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits...